Invesco
KLRS

Invesco’s Kalaris Therapeutics KLRS Stock Holding History

Invesco’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-518
Closed -$8.99K – 3990
2024
Q1 		$8.99K Hold
518
– – ﹤0.01% 3852
2023
Q4 		$8.1K Buy
518
+17
+3% +$670 ﹤0.01% 3820
2023
Q3 		$24.8K Buy
501
+36
+8% +$2.45K ﹤0.01% 3849
2023
Q2 		$36.3K Sell
465
-47
-9% -$4.47K ﹤0.01% 3834
2023
Q1 		$46.4K Sell
512
-34
-6% -$4.33K ﹤0.01% 3764
2022
Q4 		$64.4K Sell
546
-7,490
-93% -$1.27M ﹤0.01% 3889
2022
Q3 		$1.46M Buy
8,036
+7,507
+1,419% +$1.17M ﹤0.01% 2769
2022
Q2 		$48K Sell
529
-107
-17% -$11.2K ﹤0.01% 3973
2022
Q1 		$99K Buy
636
+5
+0.8% +$997 ﹤0.01% 3869
2021
Q4 		$187K Sell
631
-81
-11% -$37.6K ﹤0.01% 3797
2021
Q3 		$410K Buy
712
+82
+13% +$38K ﹤0.01% 3514
2021
Q2 		$286K Buy
+630
New +$325K ﹤0.01% 3646

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco's KLRS Position: Q2 2024 in Review

Invesco sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 518 shares — an estimated $8.99K sold.

Invesco first reported a position in KLRS in Q2 2021 and held it in 12 quarters. The position peaked at $1.46M in Q3 2022. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Invesco reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Invesco sold 518 Kalaris Therapeutics shares in Q2 2024, an estimated $8.99K.
  • Invesco first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 12 quarters.
  • Invesco's Kalaris Therapeutics position peaked at $1.46M in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.